Showing posts with label pharmaceutical. Show all posts
Showing posts with label pharmaceutical. Show all posts

Saturday, December 9, 2017

Confirmed: Snake Oil Works Better Than Pharmaceuticals

Confirmed: Snake Oil Works Better Than Pharmaceuticals | snake_and_oil | Natural Medicine Sleuth Journal Special Interests


For many centuries, the Chinese used snake oil as a treatment for joint pain, arthritis, and bursitis. They brought this folk remedy with them when they arrived in the US in the mid-1800’s to build the Transcontinental Railroad. That was backbreaking work. Synthetic pain-killers such as aspirin were not yet freely available. When the Chinese workers offered their remedy to Westerners as a palliative it was likely perceived to be a “primitive” form of “quackery” by the medical experts of that time. This is one probable origin of the derogatory meaning of the word “snake oil.”


The ironic thing about modern pharmaceuticals “snake oil,” i.e. petrochemical-derived and patented synthetic chemicals, is that they often have considerably less value than a placebo, and in certain cases may not even compare in therapeutic value to actual snake oil.


To prove the point, below are listed four remarkable studies, as cited on the National Library of Medicine’s bibliographic database known as Medline, referring to the potential therapeutic properties of sea snake and boa constrictor lipids — snake oil! — for inflammation and infection……


Boa constrictor oil has potent anti-inflammatory and significant antimicrobial activity against S. aureus and S. pyrogenes.


Pubmed Data : 1: Acta Pol Pharm. 2008 Jul-Aug;65(4):477-80.



Study Type : Human Study


Erabu sea snake oil has a beneficial effect on plasma glucose in diabetic mice.


Pubmed Data : 1: Ann Nutr Metab. 2006;50(5):425-32. Epub 2006 Jul 17.



Study Type : Animal Study


Erabu sea snake oil improves the swimming endurance of aged mice by attenuating lactate production and enhancing lactate clearance.


Pubmed Data : 1: J Nutr Sci Vitaminol (Tokyo). 2007 Dec;53(6):476-81.



Study Type : Animal Study


Additional Links


Substances : Snake Lipids : CK(15) : AC(4)


The fat from the boa constrictor has an inhibitor effect on keloid and normal dermal fibroblasts, which may contribute to the inhibition of scarring.


Pubmed Data : 1: Br J Plast Surg. 1990 Mar;43(2):183-6.



Study Type : In Vitro Study


Confirmed: Snake Oil Works Better Than Pharmaceuticals | Snake-oil_4 | Natural Medicine Sleuth Journal Special Interests


We don’t, of course, advocate consuming snake oil when other powerful, natural, and far more accessible anti-inflammatory fats are available from less sentient sources: flaxseed oil, for instance. Or, if you are really interested in the topic, here are 223 natural substances with demonstrable anti-inflammatory activity, many of which are foods, nutrients, spices and herbs.


The point here is that when age-old invectives like “snake-oil” are hurled at those advocating natural approaches to healing by those who would claim synthetic chemicals are the only “real” or evidence-based alternatives, the “insult” itself reveals a subconscious acknowledgement that practically all things produced by Nature have medicinal value.



Let’s look closer at another example of purported “snake oil”: the traditional practice among the Maori and Chinese of eating earthworms to settle an upset stomach. Long considered an obscene, disgusting, “folk medicine” practice, these 3 scientific studies tell quite a different story:


Earthworm paste has antioxidant and antiulcer properties superior to the drug ranitidine.


Pubmed Data : Eur Rev Med Pharmacol Sci. 2007 Jan-Feb;11(1):9-15.



Study Type : Animal Study


Earthworm paste has gastroprotective properties and is superior to the drug ranitidine in preventing experimentally induced gastric ulcer.


Pubmed Data : Eur Rev Med Pharmacol Sci. 2010 Mar;14(3):171-6.



Study Type : Animal Study


Earthworm powder has antioxidant and hepatoprotective properties against alcohol-induced toxicity in rats.



Study Type : Animal Study


In the first two studies, earthworms are shown superior to Ranitidine as an anti-ulcer, gastroprotective agent. Ranitidine is a chemical which blocks the H2-histamine receptors in the parietal cells in the stomach that produce hydrochloric acid, and is sold under the trade name Zantac. Until Zantac lost its patent in 1997, global sales reached 1.6 billion dollars annually. And yet despite these blockbuster sales, its value as a “medicine” compares poorly to the consumption of creatures that live beneath our feet, and who also, incidentally, make possible all the food we consume through their indispensable role in producing fecund soil.


So which is the “snake-oil,” the infatuated object of “quackery”? Synthetic chemicals excreted by a vast petrochemical-medical-industrial complex, and re-purposed and repackaged to the consumer as “medicines”? Or, natural substances and organisms traditionally used as food-medicines, sometimes for thousands of years before the advent of modern, scientism- and drug-driven medicine?


Just for the record, I won’t be eating worms any time soon. But given the choice between a chemical, with no biological or evolutionary precedent in my body, and an earthworm or sip of actual snake oil, I will gladly choose the latter.


Be sure to check out the other 40 instances of research showing Science confirming Traditional Medicine from around the world.


The post Confirmed: Snake Oil Works Better Than Pharmaceuticals appeared first on The Sleuth Journal.

Tuesday, March 28, 2017

Trump’s Pick for FDA Chief Has Drug and Biotech Industry Ties

President Trump’s pick for head of the FDA, Dr. Scott Gottlieb, has taken more than $400,000 from drug makers in the last few years alone, and Gottlieb has deep ties to the pharmaceutical industry. [1]


Gottlieb has testified multiple times on Capitol Hill concerning complex drug pricing issues, and is largely approved of by drug companies and pharmaceutical investors for FDA head. He’s on the boards of directors of several small drug and biotech companies, while also serving as an adviser to GlaxoSmithKline PLC. [2]


Brian Skorney, an investment analyst at Robert W. Baird, wrote in a research note:




“Thank God it’s Gottlieb. We view this as a favorable development for the sector.” [2]


Gottlieb is a former FDA deputy commissioner who has advocated further expediting the approval process for new medical products. He has spent the last decade as a partner at New Enterprise Associates, a large venture fund with investments in the life sciences, medical technology, and healthcare services.


These are just some of his links to the pharmaceutical industry.


Mizuho Securities USA Inc. conducted a survey of 53 pharmaceutical executives and found that 72% favored Gottlieb over other potential candidates.


Michael Carome, director of Public Citizen’s health research group and a physician, said in a statement:


“Gottlieb is entangled in an unprecedented web of Big Pharma ties. He has spent most of his career dedicated to promoting the financial interests of the pharmaceutical industry, and the U.S. Senate must reject him.” [3]


He warns:


“If the Senate does not reject Gottlieb, he will have to be recused from key decisions time and time again, otherwise there is no way to be sure he will put the public’s health over industry profits.”


The Money


Gottlieb has for years been the recipient of consulting fees from Vertex Pharmaceuticals Inc., receiving about $40,000 in 2013, $50,000 in 2014, and $66,000 in 2015. Vertex and the FDA have been in discussions since early 2016 when the FDA denied approval for Kalydeco, a cystic fibrosis drug, for a certain genetic mutation. [1]


GlaxoSmithKline paid Gottlieb $60,000 in 2015 and $100,000 in 2014 in consulting fees. Gottlieb has served as a member of the drug maker’s product investment board for several years. He also received $50,000 in 2015 from Japanese drug company Daiichi Sankyo Inc., and $11,000 in 2013 and $50,000 in 2015 from Novo Nordisk.


Valeant Pharmaceuticals International Inc. paid Gottlieb $9,000 in 2015 and about $1,000 from business unit Salix in 2014. Bristol-Myers Squibb gave him about $2,000 in 2014 and close to $10,000 in 2015.




Gottlieb also received smaller amounts from the following companies:


  • Pfizer

  • AstraZeneca

  • Baxter International

  • Baxter Healthcare

  • Bristol-Myers Squibb

  • Takeda Pharmaceuticals

  • Millennium Pharmaceuticals

  • SI-Bone

  • Insys Therapeutics

Sources:


[1] Market Watch


[2] Reuters


[3] The Hill


NBC News


Raw Story



Storable Food


About Julie Fidler:


Author Image
Julie Fidler is a freelance writer, legal blogger, and the author of Adventures in Holy Matrimony: For Better or the Absolute Worst. She lives in Pennsylvania with her husband and two ridiculously spoiled cats. She occasionally pontificates on her blog.